Koh Jing Jie Augustine, Hussein Maytham, Rao Gauri G, Li Jian, Velkov Tony
Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC 3010, Australia.
Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, VIC 3800, Australia.
Pathogens. 2022 Nov 25;11(12):1420. doi: 10.3390/pathogens11121420.
Multidrug-resistant (MDR) Gram-negative pathogens remain an unmet public health threat. In recent times, increased rates of resistance have been reported not only to commonly used antibiotics, but also to the last-resort antibiotics, such as polymyxins. More worryingly, despite the current trends in resistance, there is a lack of new antibiotics in the drug-discovery pipeline. Hence, it is imperative that new strategies are developed to preserve the clinical efficacy of the current antibiotics, particularly the last-line agents. Combining conventional antibiotics such as polymyxins with non-antibiotics (or adjuvants), has emerged as a novel and effective strategy against otherwise untreatable MDR pathogens. This review explores the available literature detailing the latest polymyxin/non-antibiotic combinations, their mechanisms of action, and potential avenues to advance their clinical application.
多重耐药(MDR)革兰氏阴性病原体仍然是一个尚未解决的公共卫生威胁。近年来,不仅对常用抗生素的耐药率有所上升,而且对多粘菌素等最后手段抗生素的耐药率也有所上升。更令人担忧的是,尽管目前存在耐药趋势,但药物研发管道中缺乏新的抗生素。因此,必须制定新的策略来保持现有抗生素的临床疗效,特别是一线药物。将多粘菌素等传统抗生素与非抗生素(或佐剂)联合使用,已成为对抗原本无法治疗的多重耐药病原体的一种新颖而有效的策略。本综述探讨了现有文献,详细介绍了最新的多粘菌素/非抗生素组合、它们的作用机制以及推进其临床应用的潜在途径。